Clinical Trial Detail

NCT ID NCT03108066
Title PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Peloton Therapeutics, Inc.
Indications

clear cell renal cell carcinoma

Therapies

PT2385

Age Groups: adult senior

Additional content available in CKB BOOST